Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Biologically Focused Therapy of Treatment-Refractory MDS Patients
- Status
- COMPLETED
- Phase
- N/A
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
- Status
- TERMINATED
- Phase
- PHASE2
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- N/A
Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- N/A
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
- Status
- RECRUITING
- Phase
- PHASE2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- Status
- RECRUITING
- Phase
- PHASE2
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
- Status
- TERMINATED
- Phase
- PHASE2
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study
- Status
- RECRUITING
- Phase
- N/A
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
Muscle Dysfunction in Patients With Haematological Diseases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
BMS-986253 in Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2